Prestige News

Total 75
Number Thumbnail Title Author Date Votes Views
75 Prestige Biopharma’s Tuznue Receives Marketing Authorization in Trinidad and Tobago
김** | 2026.09.18 | Votes 0 | Views 359
김** 2026.09.18 0 359
74 Prestige Biopharma IDC Obtains ISO 14001 and ISO 45001 Certifications
김** | 2026.09.17 | Votes 0 | Views 248
김** 2026.09.17 0 248
73 Prestige Biopharma Successfully Concludes ‘Prestige Symposium’ on Aging
김** | 2026.09.09 | Votes 0 | Views 833
김** 2026.09.09 0 833
72 Prestige Biopharma IDC CEO Ko Sang-seok Purchases Company Shares on the Open Market
김** | 2026.09.03 | Votes 0 | Views 1024
김** 2026.09.03 0 1024
71 Prestige Biopharma’s Tuznue Secures Brazilian GMP Certification, Supporting Latin American Approval Process
김** | 2026.08.25 | Votes 0 | Views 1725
김** 2026.08.25 0 1725
70 Prestige Biopharma Files Patent Application for TASA™, a Blood-Based Pancreatic Cancer Diagnostic Platform
김** | 2026.08.12 | Votes 0 | Views 1782
김** 2026.08.12 0 1782
69 Prestige Biopharma Positions PBP1710 as Its Next-Generation Growth Driver
김** | 2026.08.11 | Votes 0 | Views 2269
김** 2026.08.11 0 2269
68 Prestige Biopharma CEO Soyeon Park Purchases Approximately 70,000 Additional Shares, Bringing Total Purchases to 161,765 Shares
김** | 2026.08.04 | Votes 0 | Views 2211
김** 2026.08.04 0 2211
67 Prestige Biopharma IDC Publishes Preclinical Efficacy Results of IDC007 in International Academic Journal
김** | 2026.07.16 | Votes 0 | Views 3308
김** 2026.07.16 0 3308
66 Prestige Biopharma Unveils Follow-up Clinical Development Strategy for Pancreatic Cancer Drug Candidate PBP1510 at ESMO GI
김** | 2026.07.09 | Votes 0 | Views 4154
김** 2026.07.09 0 4154